Bristow A F, Gooding R P, Das R E
National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire.
J Endocrinol. 1990 May;125(2):191-7. doi: 10.1677/joe.0.1250191.
Three preparations of recombinant DNA-derived insulin-like growth factor-I (IGF-I) were obtained, prepared in ampoules coded 86/522, 86/720 or 87/518, and evaluated as candidate International Reference Reagents in an international collaborative study (nine laboratories in four countries) in response to a request by the World Health Organization (WHO). Immunoassay dose-response curves for each of the three preparations did not in general differ significantly from those of local standards or from those of ampouled preparations of serum-derived IGF-I which were included in the study. The estimates of ampoule contents in terms of local standards showed considerable heterogeneity; the between-laboratory variability of estimates in terms of local standards was ten times greater than the inherent variability of estimates from these systems as estimated from comparisons of coded duplicates. Bioassay data were limited, and those available were inconsistent with immunoassay data. Of the three preparations, ampoules coded 86/720 were derived from an IGF-I preparation that was heterogeneous by high-performance liquid chromatography, and stability data for the preparation 86/522 were anomalous. As a result, the ampouled preparation coded 87/518 has been established by WHO as the International Reference Reagent for IGF-I for immunoassay, with an assigned ampoule content of 3.1 micrograms/ampoule, and is available from the National Institute for Biological Standards and Control.
获得了三种重组DNA衍生的胰岛素样生长因子-I(IGF-I)制剂,分别装在编码为86/522、86/720或87/518的安瓿中。应世界卫生组织(WHO)的要求,在一项国际协作研究(四个国家的九个实验室)中对其作为国际参考制剂候选物进行了评估。这三种制剂各自的免疫测定剂量反应曲线总体上与当地标准的曲线或与研究中包含的血清衍生IGF-I安瓿制剂的曲线没有显著差异。根据当地标准对安瓿含量的估计显示出相当大的异质性;根据当地标准估计的实验室间变异性比通过编码复制品比较估计的这些系统的固有变异性大十倍。生物测定数据有限,且现有数据与免疫测定数据不一致。在这三种制剂中,编码为86/720的安瓿来自一种通过高效液相色谱分析具有异质性的IGF-I制剂,并且制剂86/522的稳定性数据异常。因此,WHO已将编码为87/518的安瓿制剂确立为免疫测定用IGF-I的国际参考制剂,指定安瓿含量为3.1微克/安瓿,可从国家生物标准与控制研究所获得。